Updated WHO guidance conditionally recommends Molnupiravir for patients with non-severe covid-19 at highest risk of hospitalization.
4 Mar, 2022 | 09:57h | UTCBMJ News Release: WHO recommends antiviral drug for patients with non-severe covid-19 at highest risk of hospital admission – BMJ
WHO News Release: WHO updates its treatment guidelines to include molnupiravir
See updated guidance: A living WHO guideline on drugs for covid-19 – BMJ
Related:
Editorial (just published): Molnupiravir’s authorisation was premature – The BMJ
FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.
8 lingering questions about the new Covid pills from Merck and Pfizer.
The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.
Merck to allow other nations to produce new COVID-19 antiviral.
Video: Merck’s Covid pill could transform treatment. Here’s how it works.
How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.
What we know — and don’t know — about Merck’s new Covid-19 pill.
Merck’s Covid-19 pill is great news but may not be a game-changer.
Video | A Pill For COVID? A Doctor Explains Molnupiravir.